The Sputnik V Vaccine from Russia is 95% Effective against Corona Virus - News
- News Archive for 2020
- News Archive for 2019
- News Archive for 2018
- News Archive for 2017
- News Archive for 2016
- News Archive for 2015
- News Archive for 2014
- News Archive for 2013
- News Archive for 2012
- News Archive for 2011
- News Archive for 2010
- News Archive for 2009
- News Archive for 2008
- News Archive for 2007
- News Archive for 2006
- News Archive for 2005
- Publications in Media
The Sputnik V Vaccine from Russia is 95% Effective against Corona Virus
Representative of the Government of the Russian Federation through the Ambassador to Indonesia Lyudmila Vorobieva said that their Sputnik V vaccine has reached a 95 percent efficacy rate against Covid-19.
"Gamaleya Research Institute has developed one of the most efficient vaccines against the corona virus in the world with an efficacy rate of more than 90 percent," Ambassador Vorobieva said.
Ambassador Vorobieva also added that currently there are more than 40 thousand volunteers taking part in the third phase of the Sputnik V vaccine. As many as 22 thousand people have been given the first dose, and more than 19 thousand have been given the second dose.
"Data showing the high efficacy of the Sputnik V vaccine give us hope that we will soon get the most important tool in the battle against the pandemic of new coronavirus infection," Ambassador Vorobieva said.
Sputnik V is an anti-Covid-19 vaccine developed by the Gamaleya Research Institute and the Russian Ministry of Defense based in Moscow. Russian President Vladimir Putin claims that the vaccine his country has found has a 95% effectiveness rate and is safe in its use.
Sputnik V is the world's first registered vaccine based on a well-studied human adenoviral bivector based platform that is safe for use. Vector is a transport technology that carries the genetics of the corona virus into cells, so that antibodies are formed in the human body. Because Sputnik V uses bivector technology, it provides stronger and longer lasting immune results than that of the vaccines developed by other pharmaceutical companies, which uses monovector technology. Currently, Sputnik V is among the top 10 vaccine candidates nearing the end of clinical trials and ready for mass production and to be registered with the World Health Organization (WHO).
"Through Phase 3 trials to humans, the Sputnik V vaccine has a high level of efficacy, 28 days after the first dose was administered. About 42 days later, after the researchers administered the second dose of injection, the data showed that the effectiveness increased to 95 percent, ” Ambassador Vorobieva added.
For information, in April 2020, President Joko Widodo communicated with Russian President Vladimir Putin to discuss efforts to increase cooperation in dealing with the corona virus pandemic. Both President Joko Widodo and President Vladimir Putin have agreed to increase contact between the two countries' health ministries.
And on September 17, 2020, the Russian Government through its Ambassador in Indonesia, Lyudmila Vorobieva, officially contacted the Ministry of Health of the Republic of Indonesia to offer the use and further development of the Sputnik V corona virus vaccine in Indonesia.
"We are ready to cooperate with the Government of Indonesia in this field. Our proposals have been submitted to several authorities related to Indonesia. In essence, we are ready to assist the Indonesian government to provide the Sputnik vaccine," Ambassador Vorobieva concluded.